Watch Andrew Lo, the economist, hedge fund manager, and finance professor at MIT Sloan, discuss his idea to bring Wall Street-style financial engineering to solving one of the most pressing medical problems of our time: curing cancer and rare diseases. Professor Lo’s proposal—the creation of a “megafund” that invests in early-stage biomedical research and drug development —holds promise for new treatments and medicine to fight cancer and other diseases. Robert Langer, the noted entrepreneur, scientist, and Institute Professor at MIT, also appears on the program to talk about bringing investors on board..
Andrew W. Lo is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management and director of the MIT Laboratory for Financial Engineering.
Believe it or not, about 20 years’ worth of potentially life-saving drugs are sitting in labs right now, untested. Why? Because they can’t get the funding to go to trials; the financial risk is too high. Roger Stein is a finance guy, and he thinks deeply about mitigating risk. He and some colleagues at MIT came up with a promising new financial model that could move hundreds of drugs into the testing pipeline. (Filmed at TED@StateStreet.)
Roger Stein wants to bring financial engineering to the world of drug funding.
Financial engineering failed dramatically in the financial crisis, but maybe it could be used to help persuade institutions to invest in cancer research. Professor Andrew Lo of MIT’s Sloan School of Management explains how to Long View columnist John Authers.
Andrew W. Lo is the Charles E. and Susan T. Harris Professor, a Professor of Finance, and the Director of the Laboratory for Financial Engineering at the MIT Sloan School of Management.
There is a growing consensus that the “bench-to-bedside” process of translating biomedical research into effective therapeutics is broken. A confluence of factors explains such pessimism but among the most widespread is the sense that the current the drug development business model is flawed. The development of new therapeutics is an expensive, lengthy, and risky process that challenges traditional funding vehicles, which are limited in size, Read More »
Recently MIT Sloan alumna Judy Lewent was inducted into the Financial Executives International Hall of Fame. A former executive vice president and chief financial officer of Merck, Lewent was recognized for her performance, leadership and integrity as a financial professional who has made significant contributions to the betterment of her organization and profession. The following is an excerpt of her remarks at the event:
“It is a momentous time for finance. As the global economy teeters on the brink, much of the world stands by holding its collective breath. This is, no doubt, a time of great anxiety. That anxiety is shared, not just by 50% of the public or 75% or even 99%. Everyone shares it.